SCHEMBL10243715

SCHEMBL10243715

CCN(CCNC(=O)OC)C(C)c1ccccc1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
HPGD P15428 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ADRA2A P08913 3/20 0.35
HTR2A P28223 2/20 0.35
KCNH2 Q12809 2/20 0.35
PGR P06401 1/20 0.35
ADRA2B P18089 1/20 0.35
HRH1 P35367 1/20 0.35
LMNA P02545 3/20 0.34
SLC22A1 O15245 2/20 0.34
ACHE P22303 2/20 0.34
CFTR P13569 1/20 0.34
HSD17B10 Q99714 1/20 0.34
SLC22A2 O15244 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP2C19 P33261 1/20 0.34
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243634 0.86 TSHR (0.40) ALDH1A1HPGDKDM4EADRA2AHTR2A
SCHEMBL10243454 0.86 KDM4E (0.37) HPGDKDM4EADRA2AHTR2AKCNH2
SCHEMBL10243117 0.86 L3MBTL1 (0.41) ALDH1A1HPGDHSD17B10TSHRMEN1
SCHEMBL10243522 0.85 MC4R (0.45) ALDH1A1ADRA2AHTR2AKCNH2PGR
SCHEMBL10244008 0.85 OPRM1 (0.40) LMNATSHRKMT2A
SCHEMBL10243705 0.84 HCRTR1 (0.43) KDM4ELMNATSHRCES2MEN1
SCHEMBL10243592 0.83 EPHX2 (0.43) ALDH1A1LMNAMEN1KMT2A
SCHEMBL10244104 0.82 HPGD (0.40) ALDH1A1HPGDKDM4ELMNAMAPK1
SCHEMBL10243497 0.82 SLC22A1 (0.43) ALDH1A1HPGDADRA2AHTR2AKCNH2
SCHEMBL10243981 0.81 ALDH1A1 (0.48) ALDH1A1HPGDLMNATSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 ALDH1A1 1939/4885HPGD 556/4885KDM4E 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.